The Oncology Institute, Inc. filed a Current Report on Form 8-K on August 3, 2026, disclosing that the company changed its legal name to Starling Oncology, Inc., effective July 28, 2026, and that its Nasdaq trading symbol changed from TOI to STLN beginning August 3, 2026.

Key Highlights

  • Name change effective July 28, 2026: The company filed a Certificate of Amendment with the Delaware Secretary of State changing its name from "The Oncology Institute, Inc." to "Starling Oncology, Inc.", effective immediately upon filing.
  • New trading symbol: The company's common stock began trading on the Nasdaq stock market LLC under the ticker symbol "STLN" on August 3, 2026.
  • No stockholder approval required: According to the filing, pursuant to Section 242 of the General Corporation Law of the State of Delaware, no stockholder approval was required because the amendment related only to a name change.
  • CUSIP number unchanged: The filing states the CUSIP number for the company's common stock remains 68236X100.
  • Stockholder rights unaffected: The filing states that neither the name change nor the symbol change affects the rights of the company's stockholders, and stockholders do not need to take any action.

Starling Oncology Name Change Details and Exchange Listing Update

According to the filing, The Oncology Institute, Inc. (NASDAQ: TOI), a Delaware corporation headquartered at 18000 Studebaker Road, Suite 800, Cerritos, CA 90703, filed a Certificate of Amendment to its Third Amended and Restated Certificate of Incorporation with the Delaware Secretary of State on July 28, 2026. The amendment changed the company's legal name to Starling Oncology, Inc. and took effect immediately upon filing.

The filing reports that the company's common stock began trading on the Nasdaq Stock Market LLC under the new ticker symbol "STLN" on August 3, 2026, replacing the prior symbol "TOI." The company also disclosed that on August 3, 2026, it issued a press release announcing both the name change and the symbol change. That press release was attached as Exhibit 99.1, and the filing notes the associated Item 7.01 disclosure is "furnished" and "shall not be deemed 'filed' for any purpose" under the Securities Act of 1933 or the Securities Exchange Act of 1934.

The document was signed by Minh Merchant, Chief Legal Officer, on behalf of the registrant. The redeemable warrants, each exercisable for one share of common stock at an exercise price of $11.50 per share, trade separately on the Nasdaq Stock Market LLC under the symbol TOIIW, according to the filing's cover page securities registration table. The filing does not indicate whether the Warrant trading symbol was also changing.

What Was Disclosed

The company disclosed a corporate name change from The Oncology Institute, Inc. to Starling Oncology, Inc., effective July 28, 2026, with a corresponding Nasdaq ticker change from TOI to STLN beginning August 3, 2026, requiring no stockholder action.